Abstract：Objective To analyze the clinical features and prognosis of patients with primary pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma.Methods A retrospective analysis was performed on the clinical data of 14 patients with primary pulmonary MALT lymphoma between 1999 and 2012. Eight patients had Ann Arbor stage ⅠE disease, 5 had stage ⅡE disease, and 1 had stage ⅢE disease. Overall, patients were treated with surgery alone (n=4), surgery followed by radiotherapy or chemotherapy (n=5), chemotherapy plus radiotherapy (n=3), or chemotherapy alone (n=2).Results The median age at diagnosis was 55 years. The male-to-female ratio was 1∶1.33. With a median follow-up of 48.3 months, no patient died during follow-up, but 3 patients had recurrence in the lungs, mediastinal lymph nodes, and right lung and meninges at 24.5, 28.5, and 36.5 months, respectively, after treatment. The 2- and 4-year progression-free survival rates were 91% and 69%, respectively.Conclusions Primary pulmonary MALT lymphoma is indolent, and most patients show a good response to treatment. Clinical treatment should be selected according to the lesion and patient's condition.
Fang Hui,Li Yexiong,Song Yongwen et al. Clinical features and treatment outcome of 14 patients with primary pulmonary mucosa-associated lymphoid tissue lymphoma [J]. Chinese Journal of Radiation Oncology, 2014, 23(1): 14-16.
[1]Isaacson P, Wright DH. Malignant lymphoma of mucosa associated lymphoid tissue: a distinctive type of B-cell lymphoma[J]. Cancer, 1983,52:1410-1416. [2] Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue[J]. Blood, 2003,101:2489-2495. [3] Oh SY, Ryoo BY, Kim WS, et al. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases[J]. Am J Hematol,2007,82:446-452. [4] Zinzani PL, Magagnoli M, Galieni P, et al. Nongastrointestinal Low-Grade Mucosa-Associated Lymphoid Tissue Lymphoma: analysis of 75 Patients[J]. J Clin Oncol,1999,17:1254-1258. [5] Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed[J]. Blood, 2000,95:802-806. [6] Ferraro P, Trastek VF, Adlakha H, et al. Primary non-Hodgkin's lymphoma of the lung[J]. Ann Thorac Surg,2000,69:993-997. [7] Ahmed S, Siddiqui AK, Rai KR, et al. Low-grade B-cell bronchial associated lymphoid tissue (BALT) lymphoma[J]. Cancer Investig,2002,20:1059-1068. [8] Parissis H. Forty years literature review of primary lung lymphoma[J/OL]. J Cardiothorac Surg,2011,6:23[2013-07-25]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056730/. [9] Sminia T, van der Brugge-Gamelkoorn GJ, Jeurissen SH, et al. Structure and function of bronchus-associated lymphoid tissue (BALT)[J]. Crit Rev Immunol,1989,9:119-150. [10] Pabst R, Gehrke I. Is the bronchus-associated lymphoid tissue (BALT) an integral structure of the lung in normal mammals, including humans[J]? Am J Respir Cell Mol Biol,1990,3:131-135. [11] Richmond I, Pritchard GE, Ashcroft T, et al. Bronchus associated lymphoid tissue (BALT) in human lung: its distribution in smokers and non-smokers[J]. Thorax,1993,48:1130-1134. [12] Tschernig T, Pabst R. Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases[J]. Pathobiology,2000,68:1-8. [13] Sung YO, Won SK, Jin SK, et al. Pulmonary marginal zone B-cell lymphoma of MALT type-What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy? Consortium for Improving Survival of Lymphoma (CISL) Study[J]. Ann Hematol,2010,89:563-568. [14] Olszewski AJ, Castillo JJ. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database[J]. Ann Oncol,2013,24:1352-1359. [15] Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma analysis of the surveillance, epidemiology, and end results database[J]. Cancer,2013,119:629-638. [16] Stefanovicl A, Morgensztern D, Fong T, et al. Pulmonary marginal zone lymphoma: A single centre experience and review of the SEER database[J]. Leukemia Lymphoma,2008,49:1311-1320. [17] Borie R, Wislez M, Thabut G, et al. Clinical characteristics and prognostic factors of pulmonary MALT lymphoma[J]. Eur Respir J,2009,34:1408-1416. [18] Girinsky T, Paumier A, Ferme C, et al. Low-dose radiation treatment in pulmonary mucosa-associated lymphoid tissue lymphoma: a plausible approach? a single-institution experience in 10 patients[J]. Int J Radiat Oncol Biol Phys,2012,83:385-389.
2014, Vol. 23 
